Diabetics and Pancreatic Cancer Risk: Diabetics, Physicians Treating Diabetics, and Loved Ones of Diabetic Should Be Aware That Some Diabetic Drugs May
Cause An Increased Risk of Pancreatic Cancer by Diabetic Cancer Lawyer Jason S. Coomer
Recent scientific studies have shown that some diabetes drugs may cause an increased
health risk of pancreatic cancer and other forms of cancer. These
incretin diabetes drugs include exenatide (Byetta, Bydureon),
liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina,
Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). If you have been
taking a diabetes drug and have been diagnosed with pancreatic cancer or you have lost a loved one who was taking a diabetes
drug and was diagnosed with pancreatic cancer, please report the
adverse action to the prescribing medical doctor and FDA as soon
as possible.
For more information on diabetes drug pancreatic
cancer lawsuits,
please feel free to send an e-mail message to Pancreatic Cancer Lawyer Jason Coomer
or go to the following pages: Januvia,
Janument,
Victoza,
Byetta, Onglyza, Bydureon, and diabetes drugs.
Diabetics Should Be Aware of Incretin Drug Pancreatic Cancer Health Risk
Incretin class diabetic drugs
work by mimicking the incretin hormones that the body usually
produces naturally to stimulate the release of insulin in response
to a meal. They are used along with diet and exercise to lower blood
sugar in adults with type 2 diabetes. Many of these incretin
diabetes drugs already include a black box warning regarding thyroid
cancer risk, but evidence is growing that these drugs may also
create an increased risk of pancreatic cancer.
Diabetics who are taking
incretin diabetes drugs including:
Januvia,
Janument,
Victoza,
Byetta,
Onglyza, Tradjenta, Oseni, and other
diabetes drugs should be aware of the cancer health risks and discuss these potential health risks with their physicians.
No comments:
Post a Comment